独特的抗体可抑制HBV病毒血症并减少HBV转基因小鼠的肝癌发

StephenW

Hum Vaccin Immunother. 2018 Mar 13:1-7. doi: 10.1080/21645515.2018.1449553. [Epub ahead of print]
The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice.Kang XZ1,2, Guo XR1,2, Chen BB1,2, Zhang TY1,2, Yuan Q1,2, Chen PJ3, Zhang J1,2, Xia NS1,2.
Author information
1a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics , School of Public Health & School of Life Science, Xiamen University , Xiamen 361102 , China.2b National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Science, Xiamen University , Xiamen 361102 , China.3c Department of Internal Medicine , National Taiwan University Hospital, National Taiwan University College of Medicine , Taipei 10002 , Taiwan.

AbstractThere are estimated 248 million individuals worldwide persistently infected with hepatitis B virus (HBV), if without timely and effective treatment, about 25%-40% of whom would develop to liver cancer, cirrhosis or other HBV related end-stage liver diseases. Our previously study has reported a unique antibody named E6F6, that recognizes HBsAg-aa119-125 and is capable of prolonged suppression of HBsAg and HBV DNA levels in mice. In this study, data revealed that the consecutive E6F6 treatments can not only effectively inhibit HBV viremia, but also significantly reduce HBV-induced hepatocarcinogenesis in DEN-treated HBV-Tg mice. Thus, this E6F6 mAb-based immunotherapy, used alone or in combination with current anti-viral therapies, may provide a promising pathway for the treatment of chronic hepatitis B.


KEYWORDS: E6F6; Hepatitis B virus; Hepatocarcinogenesis; Therapeutic antibody

PMID:29533134DOI:10.1080/21645515.2018.1449553

StephenW

Hum Vaccin Immunother。 2018年3月13日：1-7。 doi：10.1080 / 21645515.2018.1449553。 [电子版提前打印]
独特的抗体可抑制HBV病毒血症并减少HBV转基因小鼠的肝癌发生。
康XZ1,2，郭XR1,2，陈BB1,2，张TY1,2，袁Q1,2，陈PJ3，张J1,2，夏NS1,2。
作者信息

1
    厦门大学公共卫生学院生命科学学院分子疫苗与分子诊断国家重点实验室，厦门361102
2
    b厦门大学公共卫生学院生命科学学院传染病诊断与疫苗研究所，厦门361102
3
    c台湾大学医学院内科，台湾大学医学院，台湾10002，台湾。

抽象

据估计，全世界有2.48亿人持续感染乙型肝炎病毒（HBV），如果没有及时有效的治疗，其中约25％-40％会发展成肝癌，肝硬化或其他与HBV有关的终末期肝病。我们之前的研究报道了一种名为E6F6的独特抗体，其识别HBsAg-aa119-125，并且能够长期抑制小鼠中的HBsAg和HBV DNA水平。在这项研究中，数据显示连续的E6F6治疗不仅可以有效抑制HBV病毒血症，而且可以显着降低DEN处理的HBV-Tg小鼠中HBV诱导的肝癌发生。因此，这种基于E6F6 mAb的免疫疗法，单独使用或与当前的抗病毒治疗联合使用，可能为治疗慢性乙型肝炎提供了一条有前途的途径。
关键词：

E6F6;乙型肝炎病毒;肝癌;治疗性抗体

结论：
    29533134
DOI：
    10.1080 / 21645515.2018.1449553